Clinical Trial Update: HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada

View source ↗

Summary

This clinical trial update reports real-world outcomes of trastuzumab deruxtecan (Enhertu) in Canadian patients with unresectable or metastatic breast cancer, i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Low-expressing Breast Cancer
• Unresectable Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Unresectable Breast Cancer, Metastatic Breast Cancer | Status: COMPLETED